ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 977-985

  Park, Ga Bin ^a   Choi, Yunock ^a   Kim, Yeong Seok ^a   Lee, Hyun Kyung ^b   Kim, Daejin ^a   Hur, Dae Young ^a  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

B cell; Bax; EBV; JNK; p38 MAPK; ROS; Sorafenib

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; SORAFENIB;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; EBV TRANSFORMED B CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PHOSPHORYLATION; PRIORITY JOURNAL;

APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; HERPESVIRUS 4, HUMAN; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEOPLASMS; NIACINAMIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES;

EID: 84896728887     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2252     Document Type: Article

References (37)

1. Young LS and Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768, 2004.
2. Kuppers R: B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3: 801-812, 2003.
3. Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844, 2006.
4. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
5. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
6. Kane RC, Farrell AT, Saber H, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278, 2006.
7. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
8. Yang SY, Cui CL, Chi ZH, et al: Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion. Zhonghua Yi Xue Za Zhi 92: 2998-3000, 2012 (In Chinese).
9. Galanis E, Anderson SK, Lafky JM, et al: Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19: 4816-4823, 2013.
10. Cervello M, Bachvarov D, Lampiasi N, et al: Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS One 8: e65569, 2013.
11. Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
12. Huber S, Oelsner M, Decker T, et al: Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25: 838-847, 2011.
13. Lu X, Tang X, Guo W, et al: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol 102: 821-826, 2010.
14. Liu LP, Ho RL, Chen GG and Lai PB: Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18: 5662-5671, 2012.
15. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403, 2003.
16. Kim KN, Ham YM, Moon JY, et al: Acanthoic acid induces cell apoptosis through activation of the p38 MAPK pathway in HL-60 human promyelocytic leukaemia. Food Chem 135: 2112-2117, 2012.
17. Han X, Xu B, Beevers CS, et al: Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis 33: 868-875, 2012.
18. Hyun MS, Hur JM, Mun YJ, et al: BBR induces apoptosis in HepG2 cell through an Akt-ASK1-ROS-p38MAPKs-linked cascade. J Cell Biochem 109: 329-338, 2010.
19. Rahmani M, Davis EM, Crabtree TR, et al: The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27: 5499-5513, 2007.
20. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34: 9-19, 1997.
21. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
22. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998.
23. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004.
24. Fresno Vara JA, Casado E, de Castro J, et al: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
25. Chiu WH, Luo SJ, Chen CL, et al: Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. Biochem Pharmacol 83: 1159-1171, 2012.
26. Matsuzawa A and Ichijo H: Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal 7: 472-481, 2005.
27. Budihardjo I, Oliver H, Lutter M, et al: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999.
28. Green DR: At the gates of death. Cancer Cell 9: 328-330, 2006.
29. Wei MC, Zong WX, Cheng EH, et al: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
30. Wolter KG, Hsu YT, Smith CL, et al: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1281-1292, 1997.
31. Kuwana T, Mackey MR, Perkins G, et al: Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111: 331-342, 2002.
32. Ghatan S, Larner S, Kinoshita Y, et al: P38 MAP kinase mediates Bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol 150: 335-347, 2000.
33. Tsuruta F, Sunayama J, Mori Y, et al: JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23: 1889-1899, 2004.
34. Chai H, Luo AZ, Weerasinghe P, et al: Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol 3: 408-415, 2010.
35. Oh SJ, Erb HH, Hobisch A, et al: Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer 19: 305-319, 2012.
36. Sánchez-Hernández I, Baquero P, Calleros L, et al: Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett 314: 244-255, 2012.
37. Ou DL, Shen YC, Yu SL, et al: Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 70: 9309-9318, 2010.